Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
2.120
-0.090 (-4.07%)
Jan 23, 2026, 4:00 PM EST - Market closed
Kiora Pharmaceuticals Employees
Kiora Pharmaceuticals had 12 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$711,845
Market Cap
7.78M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 12 | 0 | - |
| Dec 31, 2023 | 12 | 0 | - |
| Dec 31, 2022 | 12 | -2 | -14.29% |
| Dec 31, 2021 | 14 | 0 | - |
| Dec 31, 2020 | 14 | 4 | 40.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Calidi Biotherapeutics | 28 |
| BriaCell Therapeutics | 16 |
| Abpro Holdings | 15 |
| Immuron | 7 |
| TransCode Therapeutics | 7 |
| Mustang Bio | 6 |
| Quoin Pharmaceuticals | 5 |
| Creative Medical Technology Holdings | 4 |
KPRX News
- 7 weeks ago - Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds - Newsfile Corp
- 2 months ago - Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases - Newsfile Corp
- 3 months ago - Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders - PRNewsWire
- 3 months ago - Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025 - Newsfile Corp
- 6 months ago - Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases - Newsfile Corp
- 6 months ago - Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease - Newsfile Corp
- 8 months ago - Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia - Newsfile Corp
- 9 months ago - Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 - Newsfile Corp